RT Journal Article
T1 PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
A1 Peg, Vicente
A1 López García, María Ángeles
A1 Comerma, Laura
A1 Peiró, Gloria
A1 García-Caballero Parada, Tomás
A1 Concha López, Ángel
A1 Suárez Gauthier, Ana
A1 Ruiz, Irune
A1 Rojo, Federico
K1 Antibody
K1 Breast cancer
K1 Diagnosis
K1 Immunohistochemistry
K1 Immunotherapy
K1 PD-L1
AB Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC
PB Future Medicine
SN 1479-6694
YR 2021
FD 2021
LK http://hdl.handle.net/10347/24826
UL http://hdl.handle.net/10347/24826
LA eng
NO Future Oncology 2021 17:10, 1209-1218. https://doi.org/10.2217/fon-2020-1100
NO This article was funded by Roche Diagnostics S.L. The present work was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) with European Regional Development Fund (ERDF) funding through the Institute of Health Carlos III (AES Program, PI15/00934; CIBERONC, Biomedical Research Networking Centre for Cancer). V Peg has received grants from Roche; held advisory roles for Roche, MSD and AstraZeneca and has received honoraria from Sysmex Spain
DS Minerva
RD 25 abr 2026